BOOK
Vitamin D, An Issue of Endocrinology and Metabolism Clinics of North America, E-Book
(2010)
Additional Information
Book Details
Abstract
This issue covers essential topics in endocrinology and Vitamin D, providing the most up-to-date information. Subject matter covered includes the extra-skeletal effects, nutritional needs, Vit D. assays, Rickets, osteomalacia, immune properties of Vit. D, oseoporosis, Vit. D analogs and properties, renal disease, Vit D receptor, cancer, and diabetes.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contributors | iii | ||
| Contents | vii | ||
| Foreword | xiii | ||
| Preface | xvii | ||
| Chapter 1. Vitamin D:Metabolism | 243 | ||
| SYNTHESIS OF 1,25(OH)2D3 FROM VITAMIN D3 | 243 | ||
| ROLE OF THE VITAMIN D BINDING PROTEIN IN VITAMIN D METABOLISM AND ACTION | 244 | ||
| REGULATION OF RENAL VITAMIN D HYDROXYLASES | 245 | ||
| EXTRARENAL 1-HYDROXYLASE (1α(OH)ASE) | 248 | ||
| VITAMIN D P450S IN AGING AND CHRONIC KIDNEY DISEASE | 248 | ||
| REFERENCES | 249 | ||
| Chapter 2. The Vitamin D Receptor: New Paradigms for the Regulation of Gene Expression by 1,25- Dihydroxyvitamin D3 | 255 | ||
| VDR STRUCTURE AND FUNCTION | 256 | ||
| VITAMIN D TARGET GENES | 257 | ||
| NEW APPROACHES REVEAL NEW INSIGHTS INTO VITAMIN D3–MEDIATED GENE REGULATION | 260 | ||
| GENOME-WIDE STUDIES REVEAL OVERARCHING PRINCIPLES OF GENE REGULATION | 264 | ||
| SUMMARY | 265 | ||
| ACKNOWLEDGMENTS | 265 | ||
| REFERENCES | 266 | ||
| Chapter 3. Assessment and Interpretation of Circulating 25- Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment | 271 | ||
| METHODS OF 25(OH)D QUANTITATION | 272 | ||
| DETERMINING ANALYTICAL RECOVERY OF 25(OH)D2 AND 25(OH)D3 IN HUMAN SERUM OR PLASMA | 274 | ||
| DETERMINING AND DEFINING A ‘‘NORMAL’’ CIRCULATING 25(OH)D LEVEL | 277 | ||
| CLINICAL REPORTING OF CIRCULATING 25(OH)D CONCENTRATIONS | 277 | ||
| METHODS OF 1,25(OH)2D QUANTITATION | 279 | ||
| DETERMINING AND DEFINING A ‘‘NORMAL’’ CIRCULATING 1,25(OH)2D LEVEL | 280 | ||
| STABILITY OF 25(OH)D AND 1,25(OH)2D IN SERUM OR PLASMA | 281 | ||
| STANDARDIZATION OF 25(OH)D AND 1,25(OH)2D ANALYSIS | 281 | ||
| SUMMARY | 282 | ||
| REFERENCES | 282 | ||
| Chapter 4. Low Vitamin D Status: Definition, Prevalence, Consequences, and Correction | 287 | ||
| VITAMIN D BACKGROUND AND ASSESSMENT | 287 | ||
| LOW VITAMIN D STATUS: DEFINITION AND PREVALENCE | 288 | ||
| LOW VITAMIN D STATUS: CONSEQUENCES | 291 | ||
| APPROACHES TO VITAMIN D REPLETION/SUPPLEMENTATION | 293 | ||
| WHAT IS VITAMIN D TOXICITY? | 294 | ||
| DOES THE EFFECT OF VITAMIN D2 DIFFER FROM THAT OF VITAMIN D3? | 295 | ||
| SUMMARY | 295 | ||
| REFERENCES | 295 | ||
| Chapter 5. Maternal Vitamin D Status: Implications for the Development of Infantile Nutritional Rickets | 303 | ||
| CAUSE AND EPIDEMIOLOGY OF INFANTILE NUTRITIONAL RICKETS | 304 | ||
| VITAMIN D AND CALCIUM HOMEOSTASIS IN THE MOTHER-INFANT PAIR DURING PREGNANCY AND LACTATION | 307 | ||
| CONSEQUENCES OF VITAMIN D DEFICIENCY IN MOTHER-INFANT PAIRS | 311 | ||
| RECOMMENDATIONS FOR THE PREVENTION OF VITAMIN D DEFICIENCY IN MOTHER AND CHILD | 312 | ||
| SUMMARY | 315 | ||
| REFERENCES | 316 | ||
| Chapter 6. Osteomalacia as a Result of Vitamin D Deficiency | 321 | ||
| HISTORICAL PERSPECTIVE AND SCOPE OF THE PROBLEM | 321 | ||
| CLINICAL MANIFESTATIONS OF OSTEOMALACIA | 323 | ||
| RADIOLOGICAL FEATURES OF OSTEOMALACIA | 327 | ||
| SKELETAL FRACTURES | 328 | ||
| BIOCHEMICAL CHANGES IN OSTEOMALACIA | 329 | ||
| DIAGNOSTIC APPROACH TO OSTEOMALACIA | 329 | ||
| TREATMENT OF OSTEOMALACIA | 330 | ||
| REFERENCES | 330 | ||
| Chapter 7. Genetic Disorders and Defects in Vitamin D Action | 333 | ||
| 1a-HYDROXYLASE DEFICIENCY IN CHILDREN | 334 | ||
| MUTATIONS IN THE CYP27B1 GENE AS THE MOLECULAR BASIS FOR 1a-HYDROXYLASE DEFICIENCY | 334 | ||
| MOUSE MODELS OF 1α-HYDROXYLASE DEFICIENCY | 335 | ||
| HVDRR IN CHILDREN | 337 | ||
| MUTATIONS IN THE VDR GENE AS THE MOLECULAR BASIS FOR HVDRR | 337 | ||
| MOUSE MODELS OF HVDRR | 340 | ||
| THERAPY FOR HVDRR | 340 | ||
| ALOPECIA | 341 | ||
| SUMMARY | 342 | ||
| REFERENCES | 342 | ||
| Chapter 8. Vitamin D and Fracture Prevention | 347 | ||
| GOING BEYOND BONE | 347 | ||
| VITAMIN D: ITS ROLE IN MUSCLE HEALTH | 348 | ||
| VITAMIN D: ITS ROLE IN BONE HEALTH | 349 | ||
| ADDING CALCIUM TO VITAMIN D | 350 | ||
| SUMMARY | 350 | ||
| REFERENCES | 351 | ||
| Chapter 9. Vitamin D in Kidney Disease: Pathophysiology and the Utility of Treatment | 355 | ||
| CALCIUM | 355 | ||
| CKD-MBD | 356 | ||
| NORMAL VITAMIN D PHYSIOLOGY | 356 | ||
| VITAMIN D METABOLISM IN KIDNEY DISEASE | 357 | ||
| PHOSPHORUS | 358 | ||
| ROLE OF VITAMIN D TREATMENT IN CKD-MBD | 358 | ||
| EFFECTS OF VITAMIN D ON THE CARDIOVASCULAR SYSTEM | 359 | ||
| VITAMIN D AND OVERALL SURVIVAL | 359 | ||
| OTHER POTENTIALLY BENEFICIAL EFFECTS OF VITAMIN D TREATMENT IN CKD | 359 | ||
| SUMMARY | 360 | ||
| REFERENCES | 360 | ||
| Chapter 10. Vitamin D and the Immune System: New Perspectives on an Old Theme | 365 | ||
| HISTORICAL PERSPECTIVE | 365 | ||
| VITAMIN D AND INNATE IMMUNITY | 366 | ||
| VITAMIN D AND ADAPTIVE IMMUNITY | 369 | ||
| VITAMIN D, THE IMMUNE SYSTEM AND HUMAN HEALTH | 371 | ||
| SUMMARY | 373 | ||
| REFERENCES | 373 | ||
| Chapter 11. Vitamin D: Extraskeletal Health | 381 | ||
| SOURCES OF VITAMIN D | 381 | ||
| HISTORICAL PERSPECTIVE ON EXTRASKELETAL EFFECTS OF VITAMIN D | 382 | ||
| CANCER PREVENTION | 383 | ||
| PSORIASIS | 387 | ||
| VITAMIN D AND AUTOIMMUNE DISEASES | 389 | ||
| INNATE IMMUNITY | 390 | ||
| CARDIOVASCULAR HEALTH | 393 | ||
| TYPE 2 DIABETES | 394 | ||
| SUMMARY | 394 | ||
| REFERENCES | 395 | ||
| Chapter 12. The Role of Vitamin D in Cancer Prevention and Treatment | 401 | ||
| EPIDEMIOLOGY | 401 | ||
| MECHANISMS OF THE ANTICANCER EFFECTS OF CALCITRIOL | 402 | ||
| ANTICANCER EFFECTS OF CALCITRIOL IN ANIMAL MODELS | 406 | ||
| CLINICAL STUDIES | 407 | ||
| SUMMARY | 410 | ||
| REFERENCES | 410 | ||
| Chapter 13. Vitamin D and Diabetes | 419 | ||
| TYPE 1 DIABETES | 420 | ||
| TYPE 2 DIABETES | 426 | ||
| GESTATIONAL DIABETES | 432 | ||
| VITAMIN D AND DIABETES COMPLICATIONS | 432 | ||
| SUMMARY | 434 | ||
| REFERENCES | 435 | ||
| Chapter 14. Vitamin D Analogs | 447 | ||
| PHARMACOLOGICALLY IMPORTANT VITAMIN D COMPOUNDS | 447 | ||
| CLINICAL APPLICATIONS OF VITAMIN D COMPOUNDS | 454 | ||
| CRITERIA THAT INFLUENCE PHARMACOLOGIC EFFECTS OF VITAMIN D COMPOUNDS | 457 | ||
| VDR/RXR/VDRE | 458 | ||
| MEMBRANE RECEPTORS AND NONGENOMIC EFFECTS OF VITAMIN D ANALOGS | 462 | ||
| PROPOSED MOLECULAR MECHANISMS OF ACTION OF VITAMIN D COMPOUNDS | 463 | ||
| FUTURE PROSPECTS | 463 | ||
| ACKNOWLEDGMENTS | 464 | ||
| REFERENCES | 464 | ||
| Index | 473 |